Ocuphire Pharma Hits New 52-Week High of $4.17, Up 144.71%

Ocuphire Pharma, Inc. has reached a significant milestone by hitting a new 52-week high of USD 4.17 on February 27, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 144.71% rise over the past year, significantly outperforming the S&P 500, which has seen a gain of 17.36% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology industry, Ocuphire Pharma has a market capitalization of USD 234 million. Despite its recent stock performance, the company remains in a loss-making position, with a negative return on equity of -577.66%. The stock's price-to-book ratio stands at 39.18, indicating a premium valuation relative to its book value. The stock's previous 52-week low was recorded at USD 0.65, highlighting the substantial growth it has experienced over the past year. This upward trend in Ocuphire Pharma's stock price underscores the company's evolving market position within the competitive landscape of the pharmaceuticals and biotechnology sector.